2022/08/22（月）
[Finalist] BRI Pharma Inc.
Profile
Since Dr Fukunaga discovered memory molecule, CaMKII , he has been working on age-related neurodegeneration such as AD and PD.
He defined novel therapeutic targets, fatty acid-binding proteins (FABPs) in synucleinopathy including PD and DLB.
After retirement from Tohoku University, He has developed disease-modifying drugs for age-related neurodegenerative disorders.
